Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Opinion
May 19, 2018 01:00 AM

Commentary: Trump's proposals on drug prices are right to focus on anti-competitive market practices

Chester "Chip" Davis Jr.
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Mike Morgan

    Chester "Chip" Davis Jr. is president and CEO of the Association for Accessible Medicines, a trade group for generic-drug makers.

    In his "American Patients First" plan, President Donald Trump made clear his intention to deliver on a campaign commitment to lower prescription drug costs for U.S. patients. The president and his administration proposed an array of potential policy actions designed to increase competition, spur negotiation, create incentives for lower list prices and lower out-of-pocket expenditures.

    There are proposals in the president's plan that if implemented could ensure stronger competition from generic and biosimilar medicines in the prescription drug market and thereby increase access and provide financial relief for patients at the pharmacy counter.

    The first strategic component of the blueprint calls for robust competition; such competition by generic versions of expensive brand-name medicines could significantly lower drug prices.

    According to the Food and Drug Administration, generics are priced approximately 85% less than their brand-name equivalents. And the pharmaceutical sales tracker IQVIA recently found that 90% of all generic prescriptions are filled with a co-pay of less than $20, and average only $5.47 out-of-pocket for patients.

    Last year, through his Drug Competition Action Plan, FDA Commissioner Dr. Scott Gottlieb committed to strengthening the level of generic competition in the market. In 2017, the FDA signed off on a record number of approvals for generic and biosimilar medicines. That's good news.

    But it is also important to point out that of those total approvals, a much smaller percentage actually made it to the market. That's because the FDA approval process, while vitally important, is increasingly only the equivalent of getting to the 50-yard line in a football game. There are several reasons a company may not be able to go to market with a generic drug after receiving approval. Among them, wholesaler consolidation and the partnerships the remaining large-scale wholesalers have with the nation's largest retail pharmacy chains have undeniably affected the opportunity for launches. With decreasing opportunities to secure contracts, an increasing number of generic approvals don't go to market.

    On another front, both Gottlieb and HHS Secretary Alex Azar have drawn attention to certain anti-competitive tactics, or "shenanigans," that postpone or deny generic and biosimilar entry to the marketplace. For instance, certain brand-name companies have been refusing to sell samples of their medicines at fair-market value to generic-drug makers, who need samples to get their lower-cost treatments approved by the FDA. Shortly after the president's speech, both administration leaders announced plans to have the FDA publicly disclose the companies withholding samples from generic-drug manufacturers.

    While a positive step, the reality is the companies engaging in this type of behavior have for years been called out by the media, patient advocacy leaders, members of Congress and other healthcare stakeholders, to no avail. Naming them alone won't solve this problem. Making real change will require congressional action, something the president acknowledged in his speech. A bipartisan group of congressional representatives and stakeholder groups support passing the Creates Act, which would require brand-name companies to sell generic-drug companies the samples needed for the testing required for FDA approval.

    Trump also pledged that "our patent system will reward innovation, but it will not be used as a shield to protect unfair monopolies." To realize this aspect of his vision is going to take work. Some brand-name companies are increasingly abusing the patent system by creating non-innovative "patent thickets" ahead of a primary patent's expiration.

    It takes years to litigate these patents which are often found to be invalid, needlessly delaying competition by generics and biosimilars during that time period. One manufacturer even sought to shield itself from patent review at the Patent and Trademark Office by "renting" the sovereign immunity of a Native American tribe. While we can, and should, recognize and reward true innovation, we need to be more skeptical and less tolerant of innovative legal and commercial strategies designed to protect monopolies past their due dates.

    Generic-drug and biosimilar manufacturers are committed to working with Congress and the Trump administration to fix the foundation of the U.S. market to reduce overall drug prices for the patients we serve.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Noom.jpeg
    Noom launches telehealth company to prescribe weight loss drugs
    SCOTUS_abortion
    Indiana doctor reprimanded, fined $3,000 for speaking publicly about Ohio 10-year-old's abortion
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing